Losartan Potassium Tablet
Product Images NDC 72162-2507

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72162-2507). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (F205834f 7a27 4968 9605 90a2c53ce7e9 01)

Chemical structure of Losartan Potassium, showing its molecular bonds and arrangements including aromatic rings and potassium ion representation.*

FDA Label Image

Figure 1 (F205834f 7a27 4968 9605 90a2c53ce7e9 02)

A line graph comparing the percentage of patients reaching a primary endpoint over 66 months of study between two treatments: Losartan potassium and Atenolol. The graph shows cumulative percentage on the y-axis and study months on the x-axis. Losartan potassium's curve lies below Atenolol's, indicating a lower event rate with Losartan potassium and an adjusted risk reduction of 13% (p=0.021).*

FDA Label Image

Figure 2 (F205834f 7a27 4968 9605 90a2c53ce7e9 03)

A line chart comparing the percentage of patients with fatal or non-fatal stroke over a study period in months, showing two groups treated with Atenolol (dotted line) and Losartan potassium (solid line). The chart includes a note on adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (F205834f 7a27 4968 9605 90a2c53ce7e9 04)

A comparative hazard ratio forest plot chart showing event rates of Losartan Potassium versus Atenolol for primary composite outcomes and fatal/non-fatal stroke across various patient subgroups (age, gender, race, ISH, diabetes, and history of cardiovascular disease). It depicts hazard ratios with confidence intervals indicating relative risk favoring either Losartan K or Atenolol.*

FDA Label Image

Figure 4 (F205834f 7a27 4968 9605 90a2c53ce7e9 05)

A line graph showing the percentage of patients with an event over 48 months, comparing Losartan Potassium and placebo. The graph includes a risk reduction figure of 16.1% with a p-value of 0.022. The x-axis represents time in months, and the y-axis represents the percentage of patients experiencing the event.*

FDA Label Image

Image (F205834f 7a27 4968 9605 90a2c53ce7e9 06)

FDA Label Image

Company Logo (F205834f 7a27 4968 9605 90a2c53ce7e9 07)

FDA Label Image

Label (Lbl721622507)

Losartan Potassium Tablets USP label for 50 mg strength. The label indicates a package of 30 tablets, marked Rx only, repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Unichem Laboratories Ltd. It includes storage instructions, a barcode, and a National Drug Code (NDC) 72162-2507-3.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.